Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Unlimited generation of chimeric antigen receptor (CAR) T cells from human-induced
pluripotent stem cells (iPSCs) is an attractive approach for" off-the-shelf" CAR T cell …

Clinical successes demonstrated by chimeric antigen receptor T-cell immunotherapy have
facilitated further development of T-cell immunotherapy against wide variety of diseases …

Avoiding the immune rejection of transplanted T cells is central to the success of allogeneic
cancer immunotherapies. One solution to protecting T-cell grafts from immune rejection …

The introduction of induced pluripotent stem cells (iPSCs) has opened up the potential for
personalized cell therapies and ushered in new opportunities for regenerative medicine …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

The effectiveness of chimaeric antigen receptor (CAR) T-cell immunotherapies against solid
tumours relies on the accumulation, proliferation and persistency of T cells at the tumour site …

Human iPS cell (iPSC)-derived cardiomyocytes (CMs) hold promise for drug discovery for
heart diseases and cardiac toxicity tests. To utilize human iPSC-derived CMs, the …

CD8+ T cells are important in protective immunity against intracellular pathogens and
tumors. In chronic infections or cancer, CD8+ T cells are constantly exposed to antigens and …